Clinical trials
Active, not recruiting Leukemia, Myelomonocytic, Chronic trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
36 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2006 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2012 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2018 | 2 |
| 2019 | 5 |
| 2020 | 3 |
| 2021 | 7 |
| 2022 | 5 |
| 2023 | 6 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Active, not recruiting | 36 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| M.D. Anderson Cancer Center | 6 |
| National Cancer Institute (NCI) | 6 |
| City of Hope Medical Center | 4 |
| Novartis Pharmaceuticals | 2 |
| AbbVie | 1 |
| Asan Medical Center | 1 |
| Barbara Ann Karmanos Cancer Institute | 1 |
| Center for International Blood and Marrow Transplant Research | 1 |
| Dana-Farber Cancer Institute | 1 |
| Eli Lilly and Company | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Myelomonocytic, Chronic | 36 |
| Myelodysplastic Syndromes | 27 |
| Leukemia, Myeloid, Acute | 19 |
| Myeloproliferative Disorders | 14 |
| Primary Myelofibrosis | 11 |
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 6 |
| Polycythemia Vera | 6 |
| Thrombocythemia, Essential | 6 |
| Leukemia | 5 |
| Myelodysplastic-Myeloproliferative Diseases | 5 |
Trials
Showing 1 to 25 of 36. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.